Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shenzhen Neptunus Interlong Bio-Technique

Request full access

Focusing on pharmaceutical and healthfood R&D, Manufacturing, Wholesale and Retail, Export & Import

Shenzhen, ChinaFounded 1989Health

About Shenzhen Neptunus Interlong Bio-Technique

Interlong is a biotechnology company focused on improving health and quality of life through innovative medical solutions. Operating primarily in China, Interlong serves a diverse range of clients including healthcare providers, pharmaceutical companies, and research institutions. The company leverages advanced biotechnology to develop high-quality products and services aimed at disease prevention and treatment. Interlong's business model revolves around research and development, manufacturing, and distribution of medical products, generating revenue through product sales and service contracts. The company benefits from China's growing emphasis on healthcare, driven by economic development and an aging population, which has led to increased domestic demand for medical solutions. Interlong's commitment to health is reflected in its mission to contribute to human health and improve people's lives through continuous innovation and high-quality offerings.

Source: Dealroom company data

At a glance

Status
Operational
Employees
156
Open positions
None listed
Dealroom signal
32.3/100
Industry
Health
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Nov 2022 $14M $55M CICC Fund · Qiandao Fund ↗
IPOExit Dec 1998 $0 — Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Shenzhen Neptunus Interlong Bio-Technique team growth

Shenzhen Neptunus Interlong Bio-Technique's team grew 2.6% over the past year.

1-year team growth+2.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
SecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform Minneapolis, United States Operational 19 $17M $28M
FunPepFunPep is an Industry-university collaboration bioventure company Ibaraki, Japan Operational
Arterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors Atlanta, United States Operational
LysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology Lafayette, United States Operational
TAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology Tokyo, Japan Acquired
Amygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction Palo Alto, United States Operational
AnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products Huangpu, China Acquired
Contraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics Siena, Italy Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shenzhen Neptunus Interlong Bio-Technique in the Shenzhen ecosystem

Live from Dealroom

The Shenzhen Neptunus Interlong Bio-Technique office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • CICC Fund
  • Qiandao Fund
Employees 156 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇳 China50%
🇮🇳 India16.7%
🇹🇿 Tanzania16.7%
🇬🇭 Ghana16.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shenzhen Neptunus Interlong Bio-Technique on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shenzhen Neptunus Interlong Bio-Technique’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.